Jun 11, 2015 - Conclusions: We have shown that the MedDRA classification, which is widely used in registries and clinical trials (also in rheumatology), can ...
328
Scientific Abstracts
Thursday, 11 June 2015
0.40, range 0-6) performed comparably well in predicting the three outcomes considered. CDI (mean 0.24, range 0-7) performed worst on all outcomes HAQ, SF-36 PCS and MCS. Of note, the comorbidities had almost no influence on SF-36 MCS (Table). Conclusions: We have shown that the MedDRA classification, which is widely used in registries and clinical trials (also in rheumatology), can be used to compute currently used comorbidity indices. The new RDCI performed comparably well with FCI on both HAQ and the SF-36 (both physical and mental components). CDI performed worst on all outcomes explored, but it needs to be reminded the CDI was developed to predict mortality and not functioning. References: [1] England 2014 Arthritis Care & Research [2] Groll 2005 J Clin Epid Disclosure of Interest: None declared DOI: 10.1136/annrheumdis-2015-eular.4189
THU0365
DO PATTERNS OF JOINT SWELLING OR TENDERNESS IN RHEUMATOID ARTHRITIS PATIENTS IMPACT DISEASE ACTIVITY OUTCOMES AND PAIN? IMPLICATIONS FOR CLINICAL PRACTICE
R. Arendse 1 , J. Kelsall 2 , A. Avina-Zubieta 3 , P. Baer 4 , J. Rodrigues 5 , A. Jovaisas 6 , I. Fortin 7 , M. Sheriff 8 , M. Khraishi 9 , E. Rampakakis 10 , J. Sampalis 10 , F. Nantel 11 , M. Shawi 11 , C. Tkaczyk 11 , S. Otawa 11 , A.J. Lehman 11,11 . 1 University of Saskatchewan, Saskatoon; 2 Mary Pack Arthritis Centre, Vancouver; 3 Arthritis Research Canada, Richmond; 4 Private Practice, Scarborough; 5 Clinical Research and Arthritis Centre, Windsor; 6 University of Ottawa, Ottawa; 7 CH Rimouski, Rimouski; 8 Nanaimo Regional Hospital, Nanaimo; 9 Nexus Clinical Research, St. John’s; 10 JSS Medical Research Inc, Montreal; 11 Janssen Inc Canada, Toronto, Canada Objectives: This analysis aimed to describe the pattern of specific joint involvement (tender and/or swollen) pre- and post-TNFi treatment and the impact of specific joint pattern involvement on composite score outcomes and pain. Methods: BioTRAC is an ongoing, prospective registry of patients initiating treatment for RA, AS, or PsA with infliximab (IFX) or golimumab (GLM). In this analysis, RA patients included those treated with IFX between 2002-2014 or with GLM between 2010-2014. Based on joint involvement 7 groups were created: shoulder(s), elbow(s), metacarpophalangeal (MCP(s)), wrist(s), proximal interphalangeal (PIP(s)), knee(s), and thumb(s). The impact of specific joints on disease activity indices and pain was assessed with the independent-samples t-test; linear regression produced adjusted estimates. Results: A total of 1030 RA patients were included with 5177 assessments. At baseline, MCP(s) (84.8%) and wrist(s) (66.1%) were the most commonly swollen joints. Tenderness was most frequent at baseline in these two joint types (81.1% and 70.9% of patients, respectively). Swelling/tenderness rates in all joint groups were significantly lower (p12 years) current SEP. Trajectories of SEP of subjects were defined as follows: a) stable-high: high background & high current SEP; b) upward trajectory: low background & high current SEP; c) stable low: low background & low current SEP; and d) downward trajectory: high background
